Mode
Text Size
Log in / Sign up

Left atrial appendage closure fails noninferiority test versus medical therapy in high-risk AF patients

Left atrial appendage closure fails noninferiority test versus medical therapy in high-risk AF patie…
Photo by Europeana / Unsplash
Key Takeaway
Interpret trial results cautiously; device closure did not meet noninferiority versus medical therapy for high-risk AF patients.

A multicenter randomized controlled trial in Germany compared catheter-based left atrial appendage closure to physician-directed best medical care (including direct oral anticoagulants when eligible) in 912 adult patients with atrial fibrillation at high risk for both stroke and bleeding. The primary outcome was a composite of stroke (ischemic or hemorrhagic), systemic embolism, major bleeding, or cardiovascular or unexplained death, assessed over a median follow-up of 3 years.

For the primary composite endpoint, 155 events occurred in the device group (446 patients) compared to 127 events in the medical-therapy group (442 patients). The difference in restricted mean survival time was -0.36 years (95% CI: -0.70 to -0.01), and the trial did not meet its pre-specified noninferiority margin (hazard ratio of 1.3), with a P-value of 0.44 for noninferiority. The incidence of serious adverse events was higher in the device group (82.5%) than in the medical-therapy group (77.4%).

Key limitations include the lack of reported data on specific adverse events, discontinuations, and tolerability. The trial was funded by the German Center for Cardiovascular Research. The findings indicate that, in this high-risk population with a mean CHADS-VASc score of 5.2 and HAS-BLED score of 3.0, left atrial appendage closure was not shown to be noninferior to optimized medical therapy for the composite clinical endpoint over 3 years.

Study Details

Study typeRct
Sample sizen = 446
EvidenceLevel 2
Follow-up85.2 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Catheter-based closure of the left atrial appendage is an alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation. The effectiveness of this strategy, as compared with physician-directed best medical care, in patients at high risk for stroke and bleeding is unknown. METHODS: In this multicenter randomized trial conducted in Germany, we assigned patients with atrial fibrillation and a high risk of stroke and bleeding to undergo left atrial appendage closure or to receive physician-directed best medical care (including direct oral anticoagulants, if eligible). The primary end point, tested for noninferiority, was a composite of stroke (ischemic or hemorrhagic), systemic embolism, major bleeding, or cardiovascular or unexplained death, assessed in a time-to-event analysis. The noninferiority margin was a hazard ratio of 1.3. RESULTS: A total of 912 adult patients underwent randomization. The primary end-point analysis included 446 patients who were assigned to undergo left atrial appendage closure (device group) and 442 who were assigned to physician-directed best medical care (medical-therapy group). The mean (±SD) age was 77.9±7.1 years; 38.6% of the patients were women, the mean CHADS-VASc score was 5.2±1.5 (range, 0 to 9, with higher scores indicating a greater risk of stroke), and the mean HAS-BLED score was 3.0±0.9 (range, 0 to 9, with higher scores indicating higher risk of bleeding). After a median follow-up of 3 years (interquartile range, 1.7 to 4.7), a first primary end-point event had occurred in 155 patients (incidence per 100 patient-years, 16.8) in the device group and in 127 patients (incidence per 100 patient-years, 13.3) in the medical-therapy group (difference in restricted mean survival time, -0.36 years; 95% confidence interval, -0.70 to -0.01; P = 0.44 for noninferiority). Serious adverse events occurred in 368 patients (82.5%) in the device group and 342 (77.4%) in the medical-therapy group. CONCLUSIONS: Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to physician-directed best medical care with regard to a composite end point of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death. (Funded by the German Center for Cardiovascular Research; CLOSURE-AF ClinicalTrials.gov number, NCT03463317.).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.